This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: I38 (Endocarditis, valve unspecified) | Special Copayment Reduction: V192 (Special copayment reduction for heart disease: 5% copayment for up to 30 days from the registration date) |
| B. Synonyms | Infective endocarditis (IE), bacterial endocarditis, nonbacterial thrombotic endocarditis (NBTE), acute/subacute endocarditis, Infective endocarditis |
| C. Adult onset | Can occur at any age, but frequency increases from middle age onward. About twice as common in men as in women, with higher risk in the elderly, patients with prosthetic valves, and patients with intravascular devices. |
| 1. History | Described by Osler in 1885; introduction of blood cultures and penicillin; Duke criteria established in 1994; Duke-ISCVID criteria revised in 2023 |
| 2. Causes | Staphylococcus aureus is currently the most common causative organism (about 30–35%); oral streptococci, enterococci, fungi; iatrogenic and healthcare-associated IE increasing |
| 3. Genetics | Genetic predisposition from underlying cardiac malformations (bicuspid valve, congenital heart disease); susceptibility and polymorphisms in host immune genes such as TLR2 and TLR4 |
| 4. General epidemiology | Annual incidence 30–100 per 1 million; in-hospital mortality about 15–30%; healthcare-associated and elderly IE increasing |
| 5. Pathophysiology | Endothelial injury→NBTE formation→bacterial adherence during bacteremia→vegetation formation→valve destruction and systemic embolism |
| 6. Symptoms | Fever, chills, fatigue, weight loss; embolic symptoms (cerebral infarction, splenic infarction, pulmonary embolism); heart failure symptoms may develop abruptly |
| 7. Signs | New valve murmur, Osler nodes, Janeway lesions, Roth spots, conjunctival petechiae, splinter hemorrhages of the nails, splenomegaly |
| 8. Screening | Three sets of blood cultures in patients with fever of unknown origin; consider IE immediately when fever occurs in carriers of intravascular devices; education of high-risk groups |
| 9. Diagnosis | Blood cultures, echocardiography (TTE/TEE), 2023 Duke-ISCVID criteria, FDG-PET/CT, whole-body imaging (brain and abdominal CT) |
| 10. Treatment | Prolonged intravenous antibiotics (4–6 weeks); targeted therapy based on pathogen susceptibility; consider early surgery for heart failure, embolism, or resistant organisms |
| 11. Prognosis | In-hospital mortality 15–30%; poor for Staphylococcus aureus and fungal IE; 1-year mortality 40%; recurrence rate about 5–10%/year |
| 12. Prevention | Antibiotic prophylaxis before dental procedures in high-risk groups (prosthetic valves, congenital heart disease); prevention of skin and intravascular device infections; oral hygiene management |
| 13. References | Durack DT et al. New criteria for diagnosis of infective endocarditis: utilization of specific echocardiographic findings … and 9 other papers |
The clinical description of endocarditis dates back to the autopsy report of Lazare Rivière in 1646, but systematic clinical description in the modern sense was completed in the Gulstonian Lectures that William Osler delivered at the Royal College of Physicians in 1885. Osler comprehensively described the association with chronic articular rheumatism, embolic phenomena, the role of underlying heart disease, and the poor prognosis, establishing infective endocarditis as an independent clinical disease. His name still remains today in the "Osler node," a painful nodule caused by peripheral immune complex deposition.
In the early 20th century, advances in bacteriology and blood culture techniques established the microbiological basis of IE. The first use of penicillin to treat IE in 1944 dramatically reduced the mortality of this disease. Mortality, which had previously approached nearly 100%, fell to 20–30% after the introduction of antibiotics, and subsequent advances in combination antibiotic therapy and surgical treatment contributed to improved prognosis.
The Duke criteria proposed by Durack et al. in 1994 are a systematic diagnostic framework integrating clinical, microbiological, and echocardiographic findings, and subsequently became the standard for IE research and clinical practice worldwide. In the 2000s, they were revised as the Modified Duke Criteria, adding Q fever serology. In 2023, the Duke-ISCVID criteria were published reflecting advances in imaging technology (PET/CT, SPECT/CT, MRI) and molecular diagnostics (PCR, metagenomic NGS), improving sensitivity from 70% to 84% compared with the previous criteria. Another innovation in endocarditis treatment is the concept of the Endocarditis Team (a collaborative team of cardiology, infectious diseases, thoracic surgery, and radiology), and evidence is accumulating that this multidisciplinary approach significantly improves prognosis.
The causative organisms of infective endocarditis differ by region, era, and patient population, but in developed countries Staphylococcus aureus is currently the most common causative organism, accounting for about 30–35% of all cases. The proportion of MRSA (methicillin-resistant Staphylococcus aureus) is also increasing, and it is a major cause of device-related infections. Oral streptococci (Streptococcus viridans group) were formerly the most common causative organisms, but their proportion has decreased to about 17–20% at present, and they are closely associated with dental procedures.
Enterococci (Enterococcus faecalis) are important causative organisms particularly in IE occurring in the elderly or after urological procedures or invasive gastrointestinal procedures. They account for about 10–12% of all cases. The HACEK group (Haemophilus, Aggregatibacter, Cardiobacterium, Eikenella, Kingella) are slow-growing gram-negative bacilli that cause IE with a subacute course, accounting for about 5%. Fungal endocarditis is rare (about 2–4%) but has very high mortality, occurring mainly in immunosuppressed patients, patients with long-term central venous catheters, and patients with prosthetic valves. Blood culture–negative IE accounts for about 5–10% of all cases and requires differentiation of Coxiella burnetii, Bartonella species, Brucella, and others.
ICD I38 (valve unspecified) applies when the affected valve is not specified; for clinical classification, it is preferable to subdivide into more specific codes reflecting the causative organism, the valve involved, whether it is a native valve or a prosthetic valve, and whether it is related to a cardiac device.
Direct genetic predisposition to infective endocarditis itself is limited, but the genetic background of the underlying cardiac structural abnormalities involved in the development of IE is important. Bicuspid aortic valve (BAV) is the most common heart valve malformation and increases the risk of IE, and the related NOTCH1 and GATA5 gene variants are known. Congenital heart diseases such as congenital ventricular septal defect, patent ductus arteriosus, and aortic stenosis are important structural risk factors for IE, and their genetic causes are diverse.
Studies have shown that polymorphisms in host immune response genes affect susceptibility to IE. The Arg677Trp variant of TLR2 (Toll-like receptor 2), the Asp299Gly variant of TLR4, and CARD15/NOD2 variants may be related to altered immune responses to staphylococci, and some studies have suggested an association with IE risk. However, the clinical significance of these genetic factors has not yet been established.
In connective tissue disorders such as Marfan syndrome and Loeys-Dietz syndrome, aortic valve regurgitation and mitral valve prolapse occur frequently, increasing the risk of IE. The causative genes of these disorders (FBN1, TGFBR1/2) indirectly contribute to the increased IE risk.
The incidence of infective endocarditis varies with study region and methods but is generally about 30–100 per 1 million population per year. The incidence continues to rise due to the aging population, increasing use of medical devices, and intravenous drug abuse. In particular, the incidence is markedly higher in hemodialysis patients, patients with prosthetic valves, and patients with pacemakers or defibrillators than in the general population.
It is about twice as common in men as in women, and the mean age at onset is gradually increasing, with patients aged 60 or older now accounting for about 40–50% of all cases. In-hospital mortality is about 15–30%, higher in Staphylococcus aureus IE, fungal IE, and prosthetic valve IE. It is a serious disease with a 1-year mortality reaching about 30–40%. In Korea as well, analyses of health insurance claims data have reported a continuous increase in IE incidence, and the proportion of device-related IE is increasing.
The incidence of recurrent IE is about 5–10% per year, and the risk of recurrence is high in intravenous drug users, those with a previous history of IE, and those with persistent risk factors for bacteremia. In connection with the recent opioid crisis, IE related to intravenous drug abuse has surged in some Western countries, and it mainly involves the right-sided tricuspid valve.
The pathophysiology of infective endocarditis is understood in three main stages. Stage 1: formation of nonbacterial thrombotic endocarditis (NBTE). When injury to valvular endothelial cells occurs (hemodynamic stress, turbulent flow, mechanical injury), fibrin and platelets deposit on the valve surface, forming NBTE. This becomes a substrate (nidus) susceptible to infection.
Stage 2: bacterial adherence and proliferation. When bacteremia occurs due to dental procedures, invasive gastrointestinal or urological procedures, skin infections, or other causes, bacteria in the bloodstream adhere to the NBTE surface. Strains with surface adhesion proteins (adhesins) (especially the MSCRAMM proteins of Staphylococcus aureus and FimA of streptococci) bind to extracellular matrix components such as fibronectin, laminin, and collagen and colonize the valve. The bacteria then proliferate rapidly, and fibrin, platelets, and inflammatory cells accumulate layer upon layer, forming a vegetation.
Stage 3: tissue destruction and systemic complications. Once a vegetation forms, the bacteria are protected from the immune system and secrete enzymes (proteases, hyaluronidase, etc.) that destroy valve tissue. Valve destruction leads to regurgitation, perforation, mycotic aneurysm, and annular abscess. Emboli from vegetations cause ischemic injury to the brain, spleen, kidneys, lungs (right-sided IE), and liver. Deposition of circulating immune complexes causes glomerulonephritis, vasculitis, and skin lesions (Osler nodes, Janeway lesions).
Symptoms of infective endocarditis vary with the virulence of the causative organism, the valve involved, and the presence of complications. The most common symptom is fever, occurring in more than about 90%. Fever may be persistent or intermittent; Staphylococcus aureus IE shows an acute, high-fever course, whereas streptococcal IE often shows a subacute course over several weeks. Chills, night sweats, generalized fatigue, anorexia, and weight loss accompany it.
Symptoms due to embolic complications may be the first presentation. Cerebral emboli can cause cerebral infarction, headache, focal neurological deficits, and altered consciousness, and rupture of a mycotic aneurysm causes intracerebral hemorrhage. Splenic infarction causes left upper abdominal pain, and renal infarction causes flank pain and hematuria. Right-sided IE (tricuspid involvement) causes dyspnea, pleuritic chest pain, and hemoptysis through recurrent pulmonary emboli. Heart failure symptoms (dyspnea, orthopnea, paroxysmal nocturnal dyspnea) can appear abruptly when valve destruction is severe and can lead to emergencies progressing to cardiogenic shock.
The characteristic physical examination finding of infective endocarditis is a new or changing valve murmur. However, in acute IE, valve destruction progresses rapidly, so the character of the murmur itself may change. As peripheral vascular signs, Osler nodes (painful erythematous nodules on the fingertips and toes, due to immune complex deposition) and Janeway lesions (painless hemorrhagic lesions on the palms and soles, due to septic emboli) are observed. Roth spots are retinal hemorrhagic spots seen on funduscopic examination, and conjunctival petechiae and subungual splinter hemorrhages are also markers of vasculitis and embolism.
Splenomegaly appears due to chronic IE or immune activation and may be palpable. Clubbing is rarely observed in long-standing IE. When signs of heart failure (pulmonary edema, elevated jugular venous pressure, S3 gallop) accompany fever, valve destruction due to acute IE is strongly suggested. With cerebral emboli, focal neurological signs (hemiplegia, aphasia, visual field defects) may be observed.
Early diagnosis of infective endocarditis begins with clinical suspicion. In every patient with persistent fever of unknown cause, especially those with risk factors such as underlying heart disease, prosthetic valves, intracardiac devices, recent intravascular manipulation, or intravenous drug abuse, IE must be included in the differential diagnosis. When a new valve murmur appears with fever, blood cultures and echocardiography should be performed immediately.
Blood cultures are the cornerstone of IE diagnosis, and collecting at least 3 sets (3 venipunctures, each 30–60 minutes apart) before antibiotic administration is recommended. Even when clinical instability requires immediate antibiotic administration, 2 or more sets of blood cultures should be collected as quickly as possible before starting medication. It is important to educate high-risk IE patients (prosthetic valves, intracardiac devices) to visit a medical institution immediately, even from home, when fever develops.
The 2023 Duke-ISCVID criteria are the standard for diagnosing infective endocarditis. Major criteria include persistent bacteremia with typical causative organisms (positive blood cultures) and imaging evidence of endocardial involvement (echocardiography, CT, FDG-PET/CT). Minor criteria include predisposition (underlying heart disease, drug abuse), fever, vascular phenomena, and immunological phenomena. According to these criteria, IE is classified as definite, possible, or rejected.
Echocardiography is the key test for identifying vegetations, abscesses, and new valve regurgitation. Transthoracic echocardiography (TTE) is performed as the first-line test; its specificity is high but its sensitivity is limited (about 60–70%). Transesophageal echocardiography (TEE) has a high sensitivity of about 90% and is essential for evaluating vegetations not clearly seen on TTE, abnormalities of valve structures, abscesses, and prosthetic valve IE. FDG-PET/CT is useful for identifying sites of active infection in IE related to prosthetic valves or intracardiac devices and has been included as an imaging criterion in the 2023 Duke-ISCVID criteria. Brain MRI/CT is used to identify asymptomatic embolic lesions, and abdominal and chest CT to diagnose splenic, renal, and pulmonary emboli.
The foundation of treatment for infective endocarditis is prolonged intravenous antibiotic administration. Antibiotic selection is based on blood culture results and antibiotic susceptibility testing, and empirical antibiotic treatment may be started according to the clinical situation before the causative organism is identified. The standard duration of treatment is 4–6 weeks for native valve IE and 6 weeks or more for prosthetic valve IE. For Staphylococcus aureus (including MRSA) IE, vancomycin or daptomycin is the first choice, and for MSSA, antistaphylococcal penicillins (nafcillin, oxacillin). For streptococcal IE, penicillin G or amoxicillin-class drugs are standard, and for enterococcal IE, the combination of ampicillin with gentamicin (or ceftriaxone).
Surgical treatment is applied early in the following situations: heart failure due to acute severe valve regurgitation or obstruction; infection not responding to medical treatment (uncontrolled bacteremia, new conduction disturbance, abscess formation); and vegetations that are large (>10 mm) or cause recurrent emboli; benefits of early surgery have been reported especially in Staphylococcus aureus IE and prosthetic valve IE. It is recommended that decisions on whether and when to operate be made through multidisciplinary consultation by the Endocarditis Team. Oral switch therapy can be applied in some patients after clinical stabilization, and evidence is accumulating from trials such as PARTIAL.
Infective endocarditis remains a serious disease with high mortality. In-hospital mortality is about 15–30%, and 1-year mortality reaches about 30–40%. Poor prognostic factors include Staphylococcus aureus infection, prosthetic valve IE, fungal IE, advanced age, diabetes, renal failure, immunosuppressed state, accompanying heart failure, and cerebral or great vessel embolic complications. Right-sided IE (tricuspid involvement, mainly in intravenous drug users) has a relatively favorable prognosis.
Residual valve dysfunction often persists after treatment, and about 20–40% of patients require valve surgery even after treatment. Recurrent IE is associated with continued intravenous drug abuse, failure to eliminate the source of infection, and premature discontinuation of antibiotics. Even after IE is cured, the risks of heart failure, arrhythmia, and embolism from underlying valve damage persist, so long-term follow-up management is needed. Studies have reported that the optimal combination of antibiotic therapy and surgery and treatment through a multidisciplinary Endocarditis Team significantly improve prognosis.
The key to preventing infective endocarditis is antibiotic prophylaxis in high-risk groups before invasive procedures that can cause bacteremia. The high-risk groups for which antibiotic prophylaxis is currently recommended in ACC/AHA and ESC guidelines are prosthetic valves (bioprosthetic or mechanical), previous history of IE, cyanotic congenital heart disease (uncorrected or with residual defects), and structural valve abnormalities developing after heart transplantation. In these patients, amoxicillin 2 g (or clindamycin 600 mg in case of allergy) is given orally 1 hour before dental procedures (procedures that cause bleeding).
Oral hygiene management is a very important nonpharmacological method of IE prevention. To minimize hematogenous spread of oral bacteria, high-risk groups should have regular dental checkups and active oral hygiene management. To prevent infections related to intravascular catheters and cardiac devices, thorough aseptic insertion technique, appropriate catheter maintenance, and early removal of unnecessary intravascular devices are recommended. For intravenous drug users, harm reduction programs and referral for substance abuse treatment are essential for preventing IE recurrence.
Durack DT, Lukes AS, Bright DK; Duke Endocarditis Service. New criteria for diagnosis of infective endocarditis: utilization of specific echocardiographic findings. American Journal of Medicine. 1994;96(3):200-209. DOI: 10.1016/0002-9343(94)90143-0. PMID: 8154507.
Fowler VG Jr, Miro JM, Hoen B, et al. (S. aureus Endocarditis and Bacteremia Study Group). Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA. 2005;293(24):3012-3021. DOI: 10.1001/jama.293.24.3012. PMID: 15972563.
Habib G, Lancellotti P, Antunes MJ, et al. (ESC Scientific Document Group). 2015 ESC Guidelines for the management of infective endocarditis. European Heart Journal. 2015;36(44):3075-3128. DOI: 10.1093/eurheartj/ehv319. PMID: 26320109.
Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. New England Journal of Medicine. 2006;355(7):653-665. DOI: 10.1056/NEJMoa053783. PMID: 16914701.
Li JS, Sexton DJ, Mick N, et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clinical Infectious Diseases. 2000;30(4):633-638. DOI: 10.1086/313753. PMID: 10770721.
Delgado V, Ajmone Marsan N, de Waha S, et al. (ESC Scientific Document Group). 2023 ESC Guidelines for the management of endocarditis. European Heart Journal. 2023;44(39):3948-4042. DOI: 10.1093/eurheartj/ehad193. PMID: 37622656.
Fowler VG, Durack DT, Selton-Suty C, et al. The 2023 Duke-International Society for Cardiovascular Infectious Diseases Criteria for Infective Endocarditis. Clinical Infectious Diseases. 2023;77(4):518-526. DOI: 10.1093/cid/ciad271. PMID: 37138445.
Murdoch DR, Corey GR, Hoen B, et al. (International Collaboration on Endocarditis–Prospective Cohort Study Investigators). Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century. Archives of Internal Medicine. 2009;169(5):463-473. DOI: 10.1001/archinternmed.2008.603. PMID: 19273776.
Østergaard L, Valeur N, Wang A, et al. Incidence of infective endocarditis in patients considered at moderate risk. European Heart Journal. 2019;40(19):1525-1531. DOI: 10.1093/eurheartj/ehz235. PMID: 31001620.
Iversen K, Ihlemann N, Gill SU, et al. Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis. New England Journal of Medicine. 2019;380(5):415-424. DOI: 10.1056/NEJMoa1808312. PMID: 30152252.